



October 16, 2019  
Gene Techno Science Co., Ltd.  
Code: 4584 (TSE Mothers)  
Masaharu Tani, President & CEO

## **Acquisition and Cancellation of the 6th Series of Stock Acquisition Rights (Private Placement)**

Tokyo, October 16, 2019 – Gene Techno Science Co., Ltd. (“GTS”) announced that the acquisition and cancellation of stock acquisition rights has been completed with regard to the 6<sup>th</sup> series of stock acquisition rights (“the Stock Acquisition Rights”) issued on June 19, 2018 via third-party allotment with option to revise exercise price.

### Summary of acquisition and cancellation of the Stock Acquisition Rights

Gene Techno Science Co., Ltd. 6 <sup>th</sup> series of stock acquisition rights	
Number of the Stock Acquisition Rights subject to the acquisition and cancellation	8,718 units (200 shares per unit)
Acquisition price	3,461,046 JPY (JPY 347 per unit)
Date of acquisition and cancellation	October 16, 2019
Number of the Stock Acquisition Rights after the cancellation	0 unit

### About Gene Techno Science Co., Ltd.

GTS announced GTS 3.0 “Biotech Engineering Company, striving for value creation” a new business stage starting from this fiscal year, which targeted the pediatric disease in addition to the areas GTS has been engaged in such as the orphan disease and intractable disease. By leveraging the knowhow and expertise about biotechnology acquired in the past business activities, GTS is working on the development and provision of new medicines and therapeutic treatment for the purpose of achieving comprehensive healthcare solutions for the patients suffering from these diseases as well as families and caregivers.

**Inquiries:**

Gene Techno Science Co., Ltd.

Tel: +81-3-6222-9547 Mail: [info@g-gts.com](mailto:info@g-gts.com)